US biotech firm Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals (Nasdaq: IONS) have announced that Spinraza (nusinersen), an investigational treatment for spinal muscular atrophy (SMA), has met the primary endpoint of a Phase III trial.
Cherish, the study evaluating Spinraza in later-onset SMA, found that children receiving the drug experienced a highly statistically-significant improvement in motor function compared to those who did not receive treatment. It also demonstrated a favorable safety profile in the trial.
Biogen was trading nearly 7% higher at $296.24 after two hours of trading on Monday, while California-based RNA-targeted drug discovery and development company Ionis, was up 19% at $32.28.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze